TG Therapeutics, Inc. (TGTX) Balance Sheet

The significant increase in total assets suggests a rapid buildup of working capital and inventory to support the Briumvi launch. However, the persistent negative retained earnings of $1.1 billion indicate that this growth is being fueled by external financing rather than internal value creation, which warrants caution regarding the long-term sustainability of this trajectory.

While the current ratio of 5.81 suggests adequate short-term coverage, the historical volatility in cash balances indicates that the company remains sensitive to capital market conditions. Investors should monitor whether this liquidity buffer is sufficient to fund ongoing commercial operations without requiring further dilutive financing.

The reliance on external capital to offset historical losses implies that the equity structure is currently fragile. Any future requirement for additional funding could lead to further dilution, potentially impacting the value proposition for existing shareholders if the Briumvi franchise does not reach self-sustaining profitability soon.